Company intelligence / Profile preview

Creatv Bio

Potomac, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Clinical studies show LifeTracDx can detect multiple early-stage cancers (e.g., breast, prostate, kidney) with ~80% detection rate in stage 1 and can predict response to immunotherapy and cancer progression through analysis of CTCs, CAMLs, and PGCCs using a blood-based assay. A collaboration with BriaCell showed improved progression-free survival when CAML/CTC counts drop, and other data show prognostic and predictive value across solid tumors. Company plans FDA filings for three diagnostic/companion uses[2][3][7][8].

Therapeutic areas: HematologyOncologyOther
Modalities: DeviceCompanion diagnosticsDiagnostics
Industry: Protein Biomarker Diagnostics

Partnerships

BriaCell TherapeuticsWake Forest UniversityMD Anderson Cancer CenterOver 20 academic and pharma collaborators (including NIH, DARPA, undisclosed pharma)

Beyond the preview

Go deeper on Creatv Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Creatv Bio.

Explore the full profile